Merck sac-TMT Trial Wins on Survival in Late-Line Gastroesophageal Cancer, Misses on PFS
TroFuse-015 met its overall survival goal for Merck and Kelun’s TROP2 ADC sac-TMT in 473 pretreated gastroesophageal cancer patients, but missed progression-free survival.
